Retrospective analysis of single‑agent nab‑paclitaxel in patients with platinum‑resistant non‑small cell lung cancer

Nakaya,Aya; Kurata,Takayasu; Yokoi,Takashi; Takeyasu,Yuki; Niki,Maiko; Kibata,Kayoko; Satsutani,Naoko; Torii,Yoshitaro; Katashiba,Yuichi; Ogata,Makoto; Miyara,Takayuki; Nomura,Shosaku

doi:10.3892/mco.2017.1392

Retrospective analysis of single‑agent nab‑paclitaxel in patients with platinum‑resistant non‑small cell lung cancer

Authors:
- Aya Nakaya
- Takayasu Kurata
- Takashi Yokoi
- Yuki Takeyasu
- Maiko Niki
- Kayoko Kibata
- Naoko Satsutani
- Yoshitaro Torii
- Yuichi Katashiba
- Makoto Ogata
- Takayuki Miyara
- Shosaku Nomura
View Affiliations

Affiliations: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573‑1010, Japan
Published online on: August 25, 2017 https://doi.org/10.3892/mco.2017.1392
Pages: 803-807
Copyright: © Nakaya et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A retrospective study was conducted to investigate the efficacy and toxicity of single‑agent nab‑paclitaxel in 67 patients with platinum‑resistant non‑small cell lung cancer in Kansai Medical University Hospital from August 2013 to December 2015. Overall, 25% of patients experienced disease progression, 48% exhibited a partial response, 27% had stable disease and 0% had a complete response. The median progression‑free survival (PFS) time was 4.8 months and the median overall survival time was 18.2 months. There was no statistically significant difference in PFS between patients with non‑squamous carcinoma and squamous carcinoma, or between second‑line use and post‑second‑line use. The most common severe adverse event was neutropenia, followed by interstitial lung disease, infection and fatigue. The results revealed that single agent nab‑paclitaxel was associated with an acceptable level of toxicity and a favorable response. This regimen has been developed recently, thus it has not been sufficiently evaluated its toxicity and efficacy. Additional studies to evaluate these parameters in non‑small cell lung cancer are warranted.

View Figures

View References

1	Strauss GM, Herndon JE II, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 26:5043–5051. 2008. View Article : Google Scholar : PubMed/NCBI
2	Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
3	Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
4	Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H and Renschler MF: Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Ann Oncol. 24:2390–2396. 2013. View Article : Google Scholar : PubMed/NCBI
5	Fang Y, Wang L, Xia GH and Shi MQ: Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. Asian Pac J Cancer Prev. 15:7453–7. 2014. View Article : Google Scholar : PubMed/NCBI
6	Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ and Kris MG: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 26:639–643. 2008. View Article : Google Scholar : PubMed/NCBI
7	Hu W and Zhang Z: A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer. Med Oncol. 32:4982015. View Article : Google Scholar : PubMed/NCBI
8	Sakata S, Saeki S, Okamoto I, Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishi H, et al: Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. Lung Cancer. 99:41–45. 2016. View Article : Google Scholar : PubMed/NCBI
9	American Joint Committee on Cancer: Lung cancer staging (7th). https://cancerstaging.org/references-tools/quickreferences/Documents/LungMedium.pdf#search=%27TNM+classification+7th+lung+canacer+AJCC%27Accessed. August 19–2017.
10	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
11	Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, Yablonsky PK, Bhar P and Iglesias J: A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 5:852–861. 2010. View Article : Google Scholar : PubMed/NCBI
12	Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103. 2000. View Article : Google Scholar : PubMed/NCBI
13	Yasuda K, Igishi T, Kawasaki Y, Yamamoto M, Kato K, Matsumoto S, Kotani M, Sako T, Shigeoka Y, Sugitani A, et al: Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology. 65:224–228. 2003. View Article : Google Scholar : PubMed/NCBI
14	Khan A, McNally D, Tutschka PJ and Bilgrami S: Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother. 31:1471–1474. 1997. View Article : Google Scholar : PubMed/NCBI